Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nightingale’s service expands to Europe through partnership

By Antti LuiroHead of Nordic ER Development, Analyst
Nightingale Health

Translation: Original comment published in Finnish on 6/8/2022 at 1:02 pm.

Nightingale announced it had signed a partnership with Physitrack and that it would add its Livit service as a key feature to Physitrack’s wellness product Access. The announced partnership expands Nightingale's Livit service to Germany, the UK and the Nordic countries. The partnership also makes Nightingale’s service available to occupational healthcare customers. We believe the partnership is logical for the company and the press release supports our expectations of the company's technology commercialization progressing. The press release does not impact our view of the company.

We believe that Physitrack’s and Nightingale’s offerings are intrinsically linked

Physitrack provides digital healthcare services. The company has users in 187 countries. The company offers, e.g., exercise programs and outcome tracking related to physiotherapy. The announced partnership with Nightingale is particularly related to Physitrack’s Wellness services. We understand that these include coaching for preventive well-being at work, e.g., related to physical activity and mental well-being. Thus far, Physitrack offers Wellness segment's services in the UK, Germany and the Nordic countries and the aim is to integrate Nightingale's Livit service with Physitrack's Wellness offering in these countries. The size class of Physitrack’s revenue is relatively low despite the international dimension (2021 revenue was some 82 MSEK or some 8 MEUR).

Nightingale’s service brings a new indicator to monitor the health benefits of Physitrack’s Wellness services, and we therefore believe that it complements Physitrack's offering well. Already in connection with its IPO Nightingale announced its plans to include a range of services that support health into its offering through partnerships, so we feel the partnership is natural for the company.

The partnership enables customer acquisition in new countries

With the partnership, Nightingale met the objective of a new international partnership agreement it had set for the fiscal period that ends at the end of June. In the short term, we expect the partnership to support the sales of services based on Nightingale’s tests and increase the company's customer base in the UK, Germany and the Nordic countries. We expect that the company will try to expand the cooperation later to other countries, because Physitrack has users in 187 countries.

In the longer term, we also see an opportunity for Nightingale to relay their own Livit customers to users of Physitrack coaching, which would enable new revenue streams based on the partner's own service sales. So far, Nightingale’s platform does not allow transfer of users’ test results between various partners and applications, so we do not believe that this possibility is in the cards in the near future.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures25.02.2022

202122e23e
Revenue2.13.08.9
growth-%31.9 %43.7 %197.2 %
EBIT (adj.)-5.3-10.2-13.7
EBIT-% (adj.)-253.6 %-339.8 %-154.7 %
EPS (adj.)-0.13-0.18-0.23
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

A couple of months ago, I pondered that the company’s board is very homegrown for a global growth phase, and indeed, so is the management team...
23 hours ago
by Puutaheinää
7
Damn it. I have a hunch that Barrett is leaving on his own initiative. He is the only person in the company’s management team who has managed...
23 hours ago
by omegaalpha
9
Nightingale Health Plc | Stock Exchange Release | December 12, 2025 at 2:55:00 PM EET With the expansion of the international availability of...
yesterday
by TO
2
Very good numbers for the new product! This is a good starting point, and that’s what TT also thought when deepening the cooperation.
12/11/2025, 8:34 AM
by Ossi
0
One slide from Jeffrey Barrett’s UK Biobank presentation. A sample of 266 Terveystalo employees at least indicates that the test is useful for...
12/10/2025, 7:17 PM
by Monsieur
15
Paavola’s LinkedIn post doesn’t sound like the next steps are clear at this point: As announced yesterday, after four great years at Nightingale...
12/9/2025, 6:57 PM
by KuinVain
4
Not much can be said in its brief statement. Everything else would be pure speculation. And we seem to have plenty of that.
12/9/2025, 9:10 AM
by Pertti
2
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.